Brainstorm Cell Therapeutics Inc. (BCLI) Earnings History
Annual and quarterly earnings data from 2001 to 2024
Loading earnings history...
BCLI EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
BCLI Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 100.0% | -1377.3% | 1369.0% |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export BCLI earnings history in CSV or JSON format
Free sign-in required to download data
Brainstorm Cell Therapeutics Inc. (BCLI) Earnings Overview
As of May 8, 2026, Brainstorm Cell Therapeutics Inc. (BCLI) reported trailing twelve-month net income of -$11M, reflecting +148.9% year-over-year growth. The company earned $-1.33 per diluted share over the past four quarters, with a net profit margin of 1369.0%.
Looking at the long-term picture, BCLI's historical earnings data spans multiple years. The company achieved its highest annual net income of $12M in fiscal 2024, representing a new all-time high.
Brainstorm Cell Therapeutics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including CLLS (-$35M net income, -88.6% margin), FATE (-$136M net income, -2051.1% margin), AGEN ($115,000 net income, 0.1% margin), BCLI has outperformed on profitability metrics. Compare BCLI vs CLLS →
BCLI Earnings vs Peers
Earnings metrics vs comparable public companies
BCLI Historical Earnings Data (2001–2024)
23 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $12M | +167.6% | -$12M | $2.19 | 1369.0% | -1377.3% |
| 2023 | -$17M | +29.2% | -$21M | $-4.48 | - | - |
| 2022 | -$24M | +0.7% | -$25M | $-9.93 | - | - |
| 2021 | -$24M | +23.1% | -$25M | $-10.09 | - | - |
| 2020 | -$32M | -36.8% | -$32M | $-14.09 | - | - |
| 2019 | -$23M | -66.7% | -$23M | $-13.64 | - | - |
| 2018 | -$14M | -181.7% | -$14M | $-10.05 | - | - |
| 2017 | -$5M | +0.6% | -$5M | $-3.92 | - | - |
| 2016 | -$5M | +41.3% | -$5M | $-4.00 | - | - |
| 2015 | -$8M | +8.2% | -$9M | $-6.88 | - | - |
See BCLI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BCLI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BCLI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBCLI — Frequently Asked Questions
Quick answers to the most common questions about buying BCLI stock.
Is BCLI growing earnings?
BCLI EPS is $-1.33, with earnings growth accelerating to +148.9%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-11M.
What are BCLI's profit margins?
Brainstorm Cell Therapeutics Inc. net margin is +1369.0%, with operating margin at -1377.3%. Above-average margins indicate pricing power.
How consistent are BCLI's earnings?
BCLI earnings data spans 2001-2024. The accelerating earnings trend is +148.9% YoY. Historical data enables comparison across business cycles.